Introduction
Diabetes and chronic kidney disease (CKD) are common chronic comorbid conditions, with diabetic kidney disease accounting for approximately half of all endstage renal disease cases in developed countries. 1 The US National Health and Nutrition Examination Survey (NHANES) reported that approximately 40% of survey participants with diabetes had CKD. 2 Similarly, in the UK, CKD stage 3 was reported in approximately 29% of individuals with diabetes, versus approximately 7% of those without diabetes 3 , while CKD stage 4 and 5 was reported in 2.1% versus 0.2%, and 0.3% versus 0.03% of individuals with and without diabetes, respectively. 3 Additionally, the incidence of CKD in diabetes may be under-reported, with one US primary care study indicating that CKD stages 1-5 affected 54% of individuals with type 2 diabetes (T2DM), although it had only been diagnosed in 12% of cases. 4 Rates of CKD are higher in elderly populations, and as the proportion of people aged over 60 years increases so will the rates of CKD. 5 Renal impairment complicates the management of diabetes because it increases the risk of hypoglycemia, is associated with increased risk of cardiovascular morbidity and mortality, and limits the options for glucose-lowering therapy. [6] [7] [8] [9] For example, cardiovascular disease has been reported in 53% of people with CKD, 10 and as high as 59% of people who also have T2DM. 4 The rate of hypoglycemia in people with diabetes and CKD can be double that of individuals without CKD, 11 therefore the choice of glucose-lowering therapy should account for this increased risk. 6, 8 Additionally, dose adjustments, or even drug withdrawal, may be necessary, as the clearance of some therapies may be affected. 8 However, there is a lack of evidence available, particularly from randomized clinical trials, to inform the choice of therapy and treatment goals in the management of diabetes in people with renal impairment, 8 or regarding optimal glycemic control in individuals with diabetes and more advanced CKD, for whom HbA1c targets >7.0 % may be appropriate. 8 For people with T2DM and CKD, insulin remains an appropriate option when other agents such as metformin may be contraindicated or are used at lower than standard doses. 12 While insulin requirements are generally lower in people with impaired renal function, there are no specific guidelines regarding insulin dose adjustment in this population other than general recommendations that glycemic targets should be individualized. 8 Insulin glargine 300 U/mL (Gla-300), a second-generation basal insulin, provides a more stable and prolonged pharmacokinetic and pharmacodynamic (PK/PD) profile compared with insulin glargine 100 U/mL (Gla-100). 13 Data from the phase 3 EDITION 1, 2 and 3 clinical trials showed that over 6 months, Gla-300 provided comparable glycemic control to Gla-100 in participants with T2DM, with less hypoglycemia. [14] [15] [16] Given the reduced hypoglycemia risk with Gla-300 versus Gla-100, we were interested to see if this benefit persisted in individuals with impaired renal function. The objective of this post hoc patient-level meta-analysis of EDITION 1, 2 and 3 was to investigate the impact of renal function on the safety and efficacy of Gla-300, with a focus on hypoglycemia risk.
Materials and Methods

Study design and participants
EDITION 1, 2 and 3 (NCT01499082, NCT01499095, NCT01676220) were multicenter, randomized (1:1), open-label, two-arm, parallel-group, phase 3a studies. [14] [15] [16] Briefly, eligible participants were aged ≥18 years with T2DM and receiving the following: EDITION 1, basal (≥42 U/day) and prandial insulin therapy ± metformin for ≥1 year; EDITION 2, basal insulin therapy (≥42 U/day) in combination with OADs; EDITION 3, OADs received for ≥6 months before screening and insulinnaïve. People with severe, unstable or end-stage renal disease (CKD stage 5, estimated glomerular filtration rate [eGFR] <15 mL/min/1.73 m 2 ) were excluded.
Participants were randomized (1:1) to once-daily evening injections of Gla-300 (Toujeo  , Sanofi, Paris, France) or Gla-100 (Lantus  , Sanofi), titrated to a fasting self-monitored plasma glucose (SMPG) target of 80-100 mg/dL (4.4-5.6 mmol/L); sulfonylurea use was not allowed.
In this post hoc analysis, study populations were pooled and results assessed across 
Data analysis and statistics
Efficacy outcomes were analyzed using the modified intent-to-treat (mITT) population, defined as all randomized participants who received at least one dose of study insulin and had both a baseline and at least one post-baseline efficacy assessment. The safety population comprised all participants who had received at least one dose of study insulin. 
Results
Baseline characteristics
The mITT and safety populations included 2474 and 2488 individuals, respectively.
Of the 2496 participants randomized to treatment in EDITION 1, 2 and 3, 2075 (83.1%) had a baseline eGFR ≥60 mL/min/1.73 m 2 (Gla-300: n=1039; Gla-100: 1036) and 421 (16.9%) had a baseline eGFR <60 mL/min/1.73 m 2 (Gla-300: n=208; Gla-100: 213). Baseline characteristics are summarized in Table 1 . Participants were, on average, older in the lower versus higher eGFR subgroup (approximately 65 years versus 57 years). Most participants in the study were Caucasian. Mean duration of diabetes was longer in the lower versus higher eGFR subgroup (approximately 16 years versus 12 years). Those in the lower eGFR subgroup had received approximately 1 year more of insulin therapy than those in the higher eGFR subgroup.
The proportions of participants with comorbidities reported at baseline were similar between renal function subgroups ( Supplementary Table 1 ), although there was a general trend for more participants reporting complications in the lower eGFR subgroup. The most common overall complication was diabetic sensory and motor neuropathy, reported in approximately 41% and 32% of participants in the lower and higher eGFR subgroups, respectively. Diabetic macroangiopathy was reported in an average of 9.1% and 6.1% of participants in the lower and higher eGFR subgroups, respectively ( Supplementary Table 1 ). Cardiac disorders were documented in 39.2% of participants in the lower eGFR subgroup, compared with 25.4% in the higher eGFR subgroup.
Renal function
The EDITION 1 study contributed the largest proportion of participants to the <60 mL/min/1.73 m 2 subgroup (n=188) (Supplementary Table 2 ). At baseline, the pooled average eGFR for the lower and higher renal function subgroups were 48.6 mL/min/1.73 m 2 and 85.0 mL/min/1.73 m 2 , respectively. These values did not change markedly after 6 months' treatment, regardless of eGFR subgroup or treatment arm (50.5 mL/min/1.73 m 2 and 85.0 mL/min/1.73 m 2 ).
Previous and concomitant medications
At baseline, most participants were using non-insulin antihyperglycemic medications (approximately 75% and 88% in the lower and higher eGFR subgroups, respectively), of which metformin was the most common ( Table 1 ). The proportion of participants using metformin in the lower eGFR subgroup (55%) was less than in the higher eGFR subgroup (68%). By comparison, more participants in the lower eGFR subgroup than in the higher eGFR subgroup had previously been using insulins (72% and 63%, respectively) or antihypertensive agents (86% and 74%, respectively). Most participants were using statins, irrespective of renal function (Table 1) . At month 6, there was very little change in medication usage patterns from baseline in either treatment arm or renal function subgroup ( Supplementary Table 3 ).
Glycemic control
HbA1c reduction from baseline was comparable between the Gla-300 and Gla-100 treatment groups, regardless of renal function (Least Squares [LS] mean difference 0.14 [95% confidence interval (CI): -0.04 to 0.32 and -0.03 [95% CI: -0.11 to 0.05]) in the eGFR <60 and ≥60 subgroups, respectively. There was no evidence of heterogeneity of treatment effect across subgroups (p=0.097; Figure 1A ). Similar proportions of participants achieved HbA1c target <7.0 % between treatment arms in both renal function subgroups. In the lower eGFR subgroup, 36.4% and 39.2% of participants achieved target with Gla-300 and Gla-100, respectively. In the higher eGFR subgroup, 36.2% and 34.7% of participants achieved target with Gla-300 and Gla-100 ( Figure 1B) . As observed for the HbA1c <7.0 % target, the proportion of participants achieving HbA1c target <7.5 % was comparable between the Gla-300 and Gla-100 treatment arms in both renal function subgroups. In the Gla-300 and Gla-100 treatment arms respectively, 54.9% and 58.4% of participants achieved target in the lower eGFR subgroup, and 54.0% and 51.8% of participants achieved target in the higher eGFR subgroup. The mean change in FPG from baseline to month 6 was comparable for both treatment arms and renal function subgroups (Supplementary Table 4 ). The proportion of participants attaining FPG <5.6 mmol/L was 24.8% and 32.5% in the lower eGFR subgroup, and 25.2% and 25.1% in the higher eGFR subgroup, with Gla-300 and Gla-100, respectively; for attainment of FPG <6.7 mmol/L, the proportions were 45.1% and 50.2% in the lower eGFR subgroup, and 44.5% and 46.6% in the higher eGFR subgroup, with Gla-300 and Gla-100, respectively.
Hypoglycemia
More participants in the lower versus the higher eGFR subgroup experienced ≥1 Table 5 ).
Body weight and insulin dose
Mean (SD) change in body weight from baseline to month 6 was small in both treatment groups across both renal function subgroups: 0.14 (4.06) kg and 0.42 (3.68) kg for participants in the lower eGFR subgroup; 0.59 (3.48) kg and 0.92 (3.20) kg for participants in the higher eGFR subgroup, in the Gla-300 and Gla-100 groups, respectively. At month 6, insulin dose in the lower eGFR subgroup increased from baseline by 0.30 and 0.21 U/kg (an average increase of 89.3% and 72.4%) for Gla-300 and Gla-100, respectively. In the higher eGFR subgroup, the insulin dose increase from baseline was 0.35 and 0.26 U/kg (an average increase of 117.0% and 89.2%) for Gla-300 and Gla-100, respectively (Supplementary Table 4 ). This reflected a −23.7% difference in dose increase for Gla-300 and a −18.8% difference in dose increase for Gla-100 between the lower versus higher eGFR subgroups.
Adverse events
Treatment-emergent adverse events (TEAEs) were observed more commonly in participants in the eGFR <60 versus the ≥60 mL/min/1.73 m 2 subgroup. In the lower eGFR subgroup, TEAEs were reported in 64.7% and 59.4% of participants in the Gla-300 and Gla-100 treatment groups, respectively. In the higher eGFR subgroup, TEAEs were reported in 55.8% and 52.5% of participants in the Gla-300 and Gla-100 treatment groups, respectively. The proportion of participants who experienced at least one TEAE relating to injection site reaction, hypersensitivity, cardiovascular events, and acute kidney injury, are shown in Supplementary Table 6 .
Participant satisfaction
There were no differences in patient satisfaction either by eGFR subgroup or treatment arms. The mean (SD) change in total DTSQ score from baseline to month 6 in the higher eGFR subgroup was 3.53 (6.50) and 3.93 (6.84) with Gla-300 and Gla-100, respectively. In the lower eGFR subgroup, mean change was 3.01 (6.43) and 3.30 (6.44) with Gla-300 and Gla-100, respectively. The LS mean difference (SE) between Gla-300 vs Gla-100 in total DTSQ scores after 6 months of treatment was −0.22 (0.21) in the higher eGFR subgroup, compared with −0.33 (0.46) in the lower eGFR subgroup.
Discussion
This patient-level meta-analysis from the EDITION 1, 2 and 3 trials of participants with T2DM by baseline eGFR subgroup demonstrated consistent and comparable reductions in FPG and HbA1c levels for the Gla-300 and Gla-100 groups, regardless of renal function subgroup. This finding was accompanied by a lower risk of nocturnal confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycemia with Gla-300 than Gla-100, which was not influenced by renal function. Hence, overall the pooled results presented here are consistent with the individual EDITION studies, [14] [15] [16] which also reported comparable glycemic control and reduced risk of hypoglycemia with Gla-300 compared with Gla-100. Importantly, however, these data show that this advantage of Gla-300 over Gla-100 was maintained in people with T2DM and impaired renal function. While the results of this patient-level meta-analysis are encouraging and suggest that Gla-300 therapy may also be used in people with T2DM and renal impairment, the scarcity of literature on insulin use in this population, and the post hoc nature of this analysis, highlight the need for randomized clinical trials to more fully evaluate the impact of renal function and CKD on diabetes therapy.
As expected, participants with lower eGFR experienced higher incidence and rates of hypoglycemia. While the mean insulin doses increased in both treatment arms, there was a tendency for a larger increase with Gla-300, consistent with findings reported for the overall EDITION population. [14] [15] [16] Although speculative, one possible reason underlying this greater increase in dose with Gla-300 than Gla-100 may be related to the lower bioavailability of Gla-300, owing to the greater stability of its subcutaneous depot that might make it more prone to enzymatic inactivation compared with Gla-100. 18 It is also important to consider that the dose changes observed may be a consequence of the treat-to-target design of the EDITION trials;
dose increases were to be expected given that participants switched to, or initiated, a new basal insulin in this study because they were uncontrolled on their previous treatment. In a meta-analysis of the EDITION studies, Gla-300 was associated with lower weight gain despite higher doses compared with Gla-100, 18 and the current analysis demonstrates a similar trend in participants with renal impairment.
Of note, the higher insulin doses observed in the EDITION studies with Gla-300 were not associated with an increased risk of hypoglycemic events, and the mean insulin doses were comparable between renal function subgroups in this analysis.
Differences between renal function subgroups in the relative increases of insulin dose are unlikely to account for the higher incidence of hypoglycemia in the lower eGFR subgroup as, if anything, dose increases were lower in the <60 mL/min/1.73 m 2 than the ≥60 mL/min/1.73 m 2 subgroup. Furthermore, the pooled data show that renal function did not change after treatment with either Gla-300 or Gla-100 for 6 months. These findings suggest that the observed differences between the renal subgroups in the rate and incidence of hypoglycemia were unlikely to be related to dose or dose increase, but are consistent with the higher risk for hypoglycemia reported in CKD. 11 In terms of safety, as expected, TEAE incidence was generally higher in the lower versus the higher eGFR subgroup, but there were no major differences in TEAEs between Gla-300 and Gla-100 within the two subgroups, nor between either renal function or treatment groups for injection site reactions, hypersensitivity, cardiovascular events or acute kidney injury.
The 2016 ADA guidelines do not include specific HbA1c targets for individuals with T2DM and renal impairment, although goals that are less stringent than the general target of 7.0 % (e.g. <8.0 %) are suggested for people with comorbidities. 21 Indeed, the current analysis demonstrates that HbA1c targets of <7.5 % are achievable for many people with T2DM. Furthermore, the reduced risk of hypoglycemia with Gla-300 is particularly important in this patient group, where there is a high risk of cardiovascular disease, as the experience of hypoglycemia may be associated with cardiovascular events and mortality. 22 This post hoc analysis provides data supporting the use of Gla-300 in individuals with T2DM and mild renal impairment, which will help inform and guide management decisions. The comparison with Gla-100 is important, as this is the gold standard of treatment in many countries. The lower risk of hypoglycemia with Gla-300 than Gla-100 is of particular interest as the risk of hypoglycemia is increased in people with renal impairment, 11 therefore therapy options with lower risk of hypoglycemia may be particularly beneficial in this population. Basal insulin therapy requires a balance between achieving appropriate individualized glycemic targets and minimizing or avoiding hypoglycemia. Consistent with the data here in participants with impaired renal function, a meta-analysis of EDITION 1, 2 and 3 data indicated that treatment with Gla-300 could allow people with T2DM to achieve equivalent glycemic control vs Gla-100 but with less hypoglycemia. 23 The limitations of this analysis included its post hoc nature and the exclusion of participants with severe renal impairment (CKD stage 5) from the EDITION program.
In addition, the lower number of participants with eGFR <60 mL/min/1.73 m 2 compared with the ≥60 mL/min/1.73 m 2 subgroup lead to wider confidence intervals for the hypoglycemia results for this subgroup compared with the ≥60 mL/min/1.73 m 2 subgroup, although the absolute point estimates were similar between each subgroup ( Figures 2B and 3B ). However, this analysis provided hypothesisgenerating data that may be explored further by stratifying participants according to renal function in future randomized controlled clinical studies, dedicated to evaluating insulin treatment in participants with T2DM.
In summary, as previously demonstrated overall in the EDITION program, Gla-300 had comparable effectiveness as Gla-100 in improving glycemic control in a group of challenging to treat people with T2DM and renal impairment; this clinical goal was achieved in tandem with a consistent overall reduction in the risk of nocturnal confirmed (≤70 and <54 mg/dL [≤3.9 and <3.0 mmol/L]) or severe hypoglycemia, with no significant difference between renal function subgroups. Gla-300
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